BioXcelLogo.png
BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock
February 20, 2020 07:30 ET | BioXcel Therapeutics
NEW HAVEN, Conn., Feb. 20, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced the...
BioXcelLogo.png
BioXcel Therapeutics Announces Proposed Public Offering of Common Stock
February 19, 2020 16:54 ET | BioXcel Therapeutics
NEW HAVEN, Conn., Feb. 19, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced that...
BioXcelLogo.png
BioXcel Therapeutics Announces Initiation of a Phase 2 Study Designed to Assess Agitation-Associated Biomarkers and their Response to BXCL501
February 18, 2020 07:00 ET | BioXcel Therapeutics
Study aims to support BXCL501’s potential market expansion in chronic agitation disease conditions Topline results expected in the second quarter of 2020 NEW HAVEN, Conn., Feb. 18, 2020 (GLOBE...
BioXcelLogo.png
BioXcel Therapeutics to Present at the 2020 BIO CEO & Investor Conference
February 07, 2020 07:00 ET | BioXcel Therapeutics
NEW HAVEN, Conn., Feb. 07, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence...
BioXcelLogo.png
BioXcel Therapeutics Announces FDA Clearance of IND Application for BXCL501 for the Treatment of Opioid Withdrawal Symptoms
February 05, 2020 07:00 ET | BioXcel Therapeutics
NEW HAVEN, Conn., Feb. 05, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence...
BioXcelLogo.png
BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 Study of BXCL501 for Acute Treatment of Agitation Associated with Dementia
January 07, 2020 07:00 ET | BioXcel Therapeutics
 Foundational study with plans to address multiple types of agitation associated with dementia Expands the potential therapeutic use of BXCL501 beyond neuropsychiatric disorders Topline...
BioXcelLogo.png
BioXcel Therapeutics Announces Initiation of Pivotal Phase 3 Studies of BXCL501 for Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder
December 30, 2019 07:00 ET | BioXcel Therapeutics
NEW HAVEN, Conn., Dec. 30, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches...
BioXcelLogo.png
BioXcel Therapeutics to Expand Study of BXCL701 into Multiple Advanced Solid Tumor Types
December 11, 2019 07:00 ET | BioXcel Therapeutics
NEW HAVEN, Conn., Dec. 11, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence...
BioXcelLogo.png
BioXcel Therapeutics Prepares to Initiate Pivotal Phase 3 Studies with BXCL501 Following Positive End-of-Phase 2 Meeting with FDA
December 03, 2019 07:00 ET | BioXcel Therapeutics
The Company plans to initiate the pivotal studies by year end, with topline data reported mid-2020 The first sublingual, non-invasive acute treatment candidate designed for agitation in...